#AS­CO21: Bris­tol My­er­s' so­lo, dual I/O reg­i­mens best chemo alone — with one ex­cep­tion — in first-line esophageal pa­tients

Bris­tol My­ers Squibb has made a big push in re­cent years to take its an­ti-PD(L)1 Op­di­vo — both so­lo and in com­bi­na­tion with Yer­voy — in­to gas­troin­testi­nal can­cer across a range of treat­ment set­tings. The drug­mak­er scored a big ap­proval in ad­ju­vant pa­tients with one form of the dis­ease in May, and now it’s turn­ing out most­ly pos­i­tive late-stage da­ta for an­oth­er in­di­ca­tion.

Bris­tol My­ers’ Op­di­vo plus chemother­a­py and Op­di­vo plus Yer­voy beat out chemother­a­py alone in terms of ex­tend­ing the lives of pa­tients with first-line, ad­vanced or metasta­t­ic esophageal squa­mous cell car­ci­no­ma (ES­CC) whose tu­mors can’t be re­moved, ac­cord­ing to late-break­ing da­ta from the CHECK­MATE-648 study set to be pre­sent­ed at this week­end’s #AS­CO21.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER